Image of Anticoagulant treatment in COVID‑19: a narrative review

LITERATURE

Anticoagulant treatment in COVID‑19: a narrative review


The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome coronavirus 2 (SARSCoV-
2), a member of the coronavirus family. Besides the respiratory involvement, COVID 19 patients frequently develop
a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm and complement cascade hyperactivation.
It is common to observe diffuse microvascular thrombi in multiple organs, mostly in pulmonary microvessels.
Thrombotic risk seems to be directly related to disease severity and worsens patients’ prognosis. Therefore, the correct
understanding of the mechanisms underlying COVID-19 induced prothrombotic state can lead to a thorough assessment of
the possible management strategies. Hence, we review the pathogenesis and therapy of COVID 19-related thrombosis disease,
focusing on the available evidence on the possible treatment strategies and proposing an algorithm for the anticoagulation
strategy based on disease severity


Availability

REQJ4137-2Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
https://doi.org/10.1007/s11239-020-02242-0
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous